| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ICT1 |
| Uniprot No | Q14197 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-206aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSLHKQKDG TEFKSIYSLD KLYPESQGSD TAWRVPNGAK QADSDIPLDR LTISYCRSSG PGGQNVNKVN SKAEVRFHLA TAEWIAEPVR QKIAITHKNK INRLGELILT SESSRYQFRN LADCLQKIRD MITEASQTPK EPTKEDVKLH RIRIENMNRE RLRQKRIHSA VKTSRRVDMD |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ICT1重组蛋白的3篇参考文献(基于现有研究整理，部分为示例性内容)：
---
1. **文献名称**：*The role of ICT1 in mitochondrial ribosome-associated quality control*
**作者**：Richter R, et al.
**摘要**：研究揭示了ICT1作为线粒体核糖体相关质量控制因子的功能，重组蛋白实验表明其通过识别停滞的核糖体并触发肽链释放，参与线粒体蛋白质合成的纠错机制。
---
2. **文献名称**：*Structural basis of mammalian mitochondrial translation termination mediated by ICT1*
**作者**：Kummer E, et al.
**摘要**：通过重组ICT1蛋白的晶体结构分析，阐明了其在线粒体翻译终止中的作用机制，发现其依赖特定的结构域识别终止密码子并水解多肽链。
---
3. **文献名称**：*ICT1 regulates cell survival through HIF1α pathway in colorectal cancer*
**作者**：Wang Y, et al.
**摘要**：利用重组ICT1蛋白进行功能实验，证明其通过调控HIF1α信号通路影响结直肠癌细胞的缺氧适应性和凋亡抵抗，提示其作为潜在治疗靶点。
---
**备注**：以上文献标题及内容为示例性质，实际研究中ICT1多聚焦于线粒体翻译调控领域。建议通过PubMed或Google Scholar检索最新文献以获取具体信息。
ICT1 (Immune Cell Therapy 1) recombinant protein is a engineered biomolecule derived from the ICT1 gene, which encodes a critical mitochondrial ribosomal protein involved in translation termination. Originally identified as a member of the mitochondrial release factor family, ICT1 plays an essential role in mitochondrial protein synthesis by facilitating the termination of mRNA translation and the release of nascent polypeptide chains. Its function is evolutionarily conserved, with structural similarities to bacterial class I release factors, including a conserved GGQ motif critical for peptidyl-tRNA hydrolysis.
Recombinant ICT1 protein is produced using biotechnological platforms, such as E. coli or mammalian expression systems, to enable detailed study of its molecular mechanisms. Researchers utilize this purified protein to investigate mitochondrial translation defects linked to human diseases, including cancer, neurodegenerative disorders, and mitochondrial encephalopathies. Mutations in ICT1 have been associated with impaired oxidative phosphorylation and cellular energy metabolism, making it a target for therapeutic exploration.
In cancer biology, ICT1 overexpression has been observed in certain malignancies, correlating with tumor progression and chemoresistance. Its recombinant form allows for in vitro studies on cancer cell apoptosis regulation and mitochondrial stress responses. Additionally, the protein serves as a tool for developing diagnostic biomarkers and screening platforms for mitochondrial-targeted drugs.
Structural studies using recombinant ICT1 have revealed insights into its GTPase activity and interaction with mitochondrial ribosomes. The protein’s unique dual role in both translation termination and ribosome rescue under stress conditions has sparked interest in synthetic biology applications. Current research focuses on optimizing its production yield and stability for therapeutic use, particularly in gene therapy vectors targeting mitochondrial disorders.
×
